Aflac Incorporated (NYSE:AFL – Get Free Report) Director Joseph L. Moskowitz sold 1,000 shares of the company’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $107.63, for a total value of $107,630.00. Following the completion of the transaction, the director now directly owns 25,393 shares in the company, valued at approximately $2,733,048.59. The trade was a 3.79 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Aflac Price Performance
Shares of AFL stock traded down $0.61 during trading hours on Tuesday, hitting $106.15. The company had a trading volume of 216,660 shares, compared to its average volume of 2,013,632. The company has a debt-to-equity ratio of 0.29, a quick ratio of 0.08 and a current ratio of 0.10. The firm has a market capitalization of $58.02 billion, a price-to-earnings ratio of 11.04, a PEG ratio of 3.24 and a beta of 0.93. Aflac Incorporated has a 12 month low of $79.31 and a 12 month high of $115.50. The firm’s fifty day moving average is $105.15 and its 200 day moving average is $107.73.
Aflac (NYSE:AFL – Get Free Report) last posted its earnings results on Wednesday, February 5th. The financial services provider reported $1.56 earnings per share for the quarter, missing the consensus estimate of $1.63 by ($0.07). Aflac had a return on equity of 16.20% and a net margin of 28.76%. On average, sell-side analysts predict that Aflac Incorporated will post 6.88 EPS for the current fiscal year.
Institutional Investors Weigh In On Aflac
Analysts Set New Price Targets
Several equities analysts recently weighed in on the stock. Evercore ISI cut their price objective on shares of Aflac from $104.00 to $102.00 and set an “underperform” rating on the stock in a research report on Wednesday, December 4th. Morgan Stanley raised their price target on shares of Aflac from $98.00 to $105.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. StockNews.com upgraded shares of Aflac from a “sell” rating to a “hold” rating in a report on Friday, February 14th. Keefe, Bruyette & Woods reduced their price target on Aflac from $107.00 to $104.00 and set a “market perform” rating for the company in a research report on Wednesday, February 12th. Finally, Wells Fargo & Company decreased their price target on Aflac from $104.00 to $102.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 19th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Aflac presently has a consensus rating of “Hold” and an average target price of $103.36.
View Our Latest Analysis on AFL
Aflac Company Profile
Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.
Further Reading
- Five stocks we like better than Aflac
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Tesla Stock is Oversold – Is Now the Time to Be Brave?
- Financial Services Stocks Investing
- 3 Stocks Institutions Are Quietly Dumping
- What is the Euro STOXX 50 Index?
- Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
Receive News & Ratings for Aflac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aflac and related companies with MarketBeat.com's FREE daily email newsletter.